AKT1 and non-small cell lung carcinoma: A great number of studies have demonstrated aberrant activation of p-Akt and p-ERK when EGFR-TKI resistance occurs [29], but restraining p-Akt and p-ERK expression could recover gefitinib sensitivity in NSCLC [35, 36].